This study examined the relationships between hepatitis C virus (HCV) genotypes and the routes of HCV transmission in 101 patients with chronic hepatitis C. Patients who received blood transfusions ...

The FDA has approved Zepatier for the treatment of HCV genotypes 1 and 4 infections. Zepatier has been approved by the FDA to treat hepatitis C virus genotypes 1 and 4 infections in adult patients.

Gilead Sciences announced the FDA approval of Epclusa for the treatment of hepatitis C genotypes 1 through 6 in patients coinfected with HIV, according to a press release. “Epclusa has already helped ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company's Phase 3 C-EDGE CO-STAR clinical ...

(Reuters) - The U.S. Food and Drug Administration on Thursday approved AbbVie Inc's drug to treat certain adults with chronic hepatitis C. The drug, Mavyret, aims to treat hepatitis C genotypes 1 ...

A hepatitis C genotype prevalent in the Middle East can be treated by combining existing drugs with a new antiviral. An international team of scientists, including KAIMRC’s Faisal Sanai, have had ...

(PRINCETON, N.J., OCTOBER 15, 2015) – Bristol-Myers Squibb (NYSE:BMY) today announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir) in ...

BOSTON — An investigational combination of direct-acting antiviral agents is associated with high sustained viral response rates in patients with renal impairment who are infected with chronic ...

Epclusa (sofosbuvir/velpatasvir) is a brand-name prescription medication. It’s approved by the Food and Drug Administration (FDA) to treat hepatitis C, which is an ...

In 2012, the hepatitis C universe changed forever when Gilead's Sovaldi was approved. Finally, there was an excellent drug that could eliminate the infection almost all the time. But some strains of ...

PITTSBURGH and HYDERABAD, India, Jan. 26, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited is expanding its hepatitis C licensing agreement ...

Hepatitis C is a serious blood borne disease that can cause severe liver damage and impacts over 2.5 million Americans. While the disease can be treated, treatment is not yet universally available and ...